Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple MyelomaSundar Jagannath, Peter M. Voorhees, Noopur Raje et al.|Journal of Clinical Oncology|2025Cited by 107
Biomarker Correlates of Response to Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma from CARTITUDE-1, a Phase 1b/2 Open-Label Study, at the ~3 Year Follow-upRocío Montes de, Enrique Zudaire, Junchen Gu et al.|Blood|2023Cited by 9